Related Experiment Video
Updated: Jun 25, 2025
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
404
Expression of Glutathione Peroxidase4 in Patients with Esophageal Squamous Carcinoma and Its Impact on the
Chen Chen1, Wendong Gu1, Yingjie Shao1
1Department of Radiation Oncology, Changzhou, China.
Annals of Clinical and Laboratory Science
|May 27, 2024
Summary
Glutathione peroxidase-4 (GPX4) is highly expressed in esophageal squamous cell carcinoma (ESCC), impacting radiosensitivity. Inhibiting GPX4 enhances ESCC radiosensitivity, offering prognostic potential.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Glutathione peroxidase-4 (GPX4) plays a role in ferroptosis and lipid metabolism.
- GPX4's role in esophageal squamous cell carcinoma (ESCC) and its influence on treatment response require further investigation.
Purpose of the Study:
- To investigate GPX4 expression in ESCC tissues.
- To determine the association between GPX4 expression and clinical parameters in ESCC.
- To evaluate the impact of GPX4 on the radiosensitivity of ESCC cells both in vitro and in vivo.
Main Methods:
- Immunohistochemistry was used to assess GPX4 expression in 180 ESCC and adjacent tissue samples.
- In vitro studies utilized apoptosis and colony formation assays.
- In vivo efficacy was evaluated using a nude mouse xenograft model.
Main Results:
- GPX4 expression was significantly higher in ESCC tumor tissues compared to adjacent tissues.
- Lower GPX4 expression correlated with longer overall survival and was associated with pathological grade.
- GPX4 silencing or inhibition increased radiosensitivity, elevated reactive oxygen species (ROS) levels, and reduced tumor growth in vivo.
Conclusions:
- GPX4 is upregulated in ESCC and serves as a potential prognostic biomarker.
- Targeting GPX4 can enhance the radiosensitivity of esophageal squamous cell carcinoma.
